Michelle Xia on Akeso's Rapid Expansion and Groundbreaking Drug Development | Michelle Xia, CEO, Akeso Inc. 00:10:00

Share On Facebook Share On Twitter

Michelle Xia, Ph.D., CEO of Akeso, joins the Business of Biotech to discuss the company's remarkable growth and its impressive portfolio. Akeso boasts 20 drug development programs, including 12 clinical-stage antibodies, six bi-specific antibodies (two in clinical stages), and four FDA-approved IND antibodies. With 22 initiated clinical trials, Xia sheds light on how Akeso has achieved such extraordinary progress and what the future holds for this trailblazing biopharmaceutical company.

Recent Videos